Beam Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Beam Therapeutics's estimated annual revenue is currently $67.7M per year.
- Beam Therapeutics received $135.0M in venture funding in March 2019.
- Beam Therapeutics's estimated revenue per employee is $124,742
- Beam Therapeutics's total funding is $689M.
- Beam Therapeutics's current valuation is $4.6B. (January 2022)
- Beam Therapeutics has 543 Employees.
- Beam Therapeutics grew their employee count by 45% last year.
Beam Therapeutics Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Beam Therapeutics?
Beam Therapeutics is developing precision genetic medicines for serious diseases. Co-founded by scientific pioneers known for advancing CRISPR gene editing, were the first company to pursue development of new therapies using CRISPR base editing technology. We aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. WHO WE ARE Beam is creating precision genetic medicines through base editing WHY WE DO IT Our dream is to provide life-long cures for patients suffering from serious diseases WHO WE ARE AND HOW WE WORK TOGETHER The Beam Team: A community of fearless innovators Rigorous and honest in our research Listening with open minds Committed to each otherkeywords:N/A
Number of Employees
Employee Growth %
Beam Therapeutics News
Beam Therapeutics Inc, a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United...
Pfizer's 4 year partnership with Beam Therapeutics on developing treatments for 3 rare genetic diseases involves $300 million upfront to speed...
Beam Therapeutics (NASDAQ:BEAM) is a preclinical stage gene editing company which has a $3.7bn valuation because its founder happens to be...
Beam Therapeutics (BEAM), a Cambridge, Mass., genome-editing startup, raised $180 million in an initial public offering Wednesday after increasing the number of shares it offered to investors by 48 percent. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET START ...
The company declined to comment because it is in a quiet period in connection with the filing. Beam’s last major financing was a $135 million Series B funding round that it raised in March. It launched in May of last year with an $87 million Series A round after operating in stealth mode for a ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Beam Therapeutics Funding
|2018-05-15||$87.0M||A||F-Prime Capital Partners||Article|